Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: New substituted 4-arylaminoquinazolines as potent inhibitors of breast tumor cell lines: In vitro and docking experiments
Author: de Oliveira, AN
Bocca, CC
Carvalho, JE
Ruiz, ALG
Silva, TP
Rittner, R
Hoehr, NF
Abstract: The arylquinazolines represent significant advances in the clinical management of breast cancer. Nevertheless some confirmatory studies must be considered to foster the use of anti-EGFR therapies including safety and clinical use. Two 4-arylaminoquinazoline derivatives, recently synthesized, were tested as kinase inhibitors and their citotoxicities showed potent growth inhibitory activity in breast tumor cell lines (MCF-7). The predicted complex structure of quinazoline inhibitors with EGFR protein from molecular docking provided a stereoview of the binding site correlated with structure activity, affording important information about structure-based drug design. (C) 2010 Published by Elsevier Masson SAS.
Subject: 4-arylaminoquinazolines
Breast cancer
In vitro inhibition
Molecular docking
Country: França
Editor: Elsevier France-editions Scientifiques Medicales Elsevier
Citation: European Journal Of Medicinal Chemistry. Elsevier France-editions Scientifiques Medicales Elsevier, v. 45, n. 9, n. 4339, n. 4342, 2010.
Rights: fechado
Identifier DOI: 10.1016/j.ejmech.2010.04.034
Date Issue: 2010
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
WOS000281568600100.pdf630 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.